We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees
An Oxford spin-out is developing advanced tiny metallic mesh tube devices invented by engineers and clinicians at the University to treat patients suffering from brain aneurysms.
45 innovators from Mexico, Brazil, and Chile spent two weeks in London in December, learning the business of innovation from Isis Enterprise (IE).
Celleron Therapeutics is developing personalised medicine for cancer patients. The company has announced results from its first human trial in patients at Oxford’s Churchill Hospital with advanced treatment-resistant aggressive cancer.
Nasdaq-listed Oxford spinout Summit Therapeutics has hit its first research milestone as part of a multiyear strategic alliance with the University of Oxford. The collaboration is focussed on developing future-generation utrophin modulators for the potential treatment of all patients with the progressive muscle wasting disorder Duchenne Muscular Dystrophy.
Summit Therapeutics and Oxford have announced a multi-year extension of their strategic alliance for the development of utrophin modulators to treat Duchenne Muscular Dystrophy.
Perspectum announced today it has been given US FDA clearance to market its test for diagnosing and measuring liver disease.